Shunt for redistributing atrial blood volume

Abstract

A shunt for regulating blood pressure between a patient's left atrium and right atrium comprises an anchor comprising a neck region, first and second end regions, and a conduit affixed with the anchor that formed of a biocompatible material that is resistant to transmural and translation tissue ingrowth and that reduces a risk of paradoxical embolism.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of U.S. application Ser. No. 15 / 449,834, filed Mar. 3, 2017, now U.S. Pat. No. 10,076,403, the entire contents of which are incorporated by reference herein.FIELD OF THE INVENTION[0002]This application generally relates to percutaneously placed implants and methods for redistributing blood from one cardiac chamber to another to address pathologies such as heart failure (HF), myocardial infarction (MI) and pulmonary arterial hypertension (PAH).BACKGROUND OF THE INVENTION[0003]Heart failure is the physiological state in which cardiac output is insufficient to meet the needs of the body or to do so only at a higher filing pressure. There are many underlying causes of HF, including myocardial infarction, coronary artery disease, valvular disease, hypertension, and myocarditis. Chronic heart failure is associated with neurohormonal activation and alterations in autonomic control. Although these co...

AI Technical Summary

Benefits of technology

The present invention provides a durable interatrial shunt that maintains luminal patency for extended periods of time and reduces the risk of paradoxical embolism. The shunt enables redistribution of interatrial blood volumes and pressure imbalances while also reducing the impact of the manner in which it is implanted. The shunt is designed to control LAP by transferring a small portion of the blood normally flowing from the left atrium to the left ventricle and diverting it instead to the right atrium, thereby modestly reducing LV end-diastolic filling volume. The anticipated clinical effect of the reduced LAP is expected to relieve or even prevent pulmonary congestive symptoms. The device can be used for treating heart failure and pulmonary congestion, reducing the left atrial pressure and left ventricular end diastolic pressure. Other heart pathologies that may be treated include myocardial infarction.

Problems solved by technology

Accordingly, even a modest reduction in LV end-diastolic volume leads to a substantial fall in LV end-diastolic pressure.

Images